WeTrials
Recruiting

A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy

What is this study?

This study looks at the best way to use maintenance therapy after chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal cancer. It compares taking the targeted drug olaparib for one year versus two years, with or without the blood-vessel-blocking drug bevacizumab, to see which approach works best.

Who can participate?

You might be eligible if you have been recently diagnosed with advanced stage III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with specific cell types or a BRCA1/2 gene mutation. Your cancer must have also responded well to your initial platinum-based chemotherapy.

What will happen?

Participants will be assigned to receive specific treatments involving olaparib and potentially bevacizumab for either one or two years. You will also undergo regular check-ups, imaging scans, and routine tissue or fluid sample tests to monitor your health and how the treatment is working.

Where and when?

This study is currently recruiting participants at multiple locations across the United States, including sites in Alabama and Alaska. Your care team can help you find the most convenient location.

Key Points
  • 1Testing how long maintenance therapy needs to last after chemotherapy.
  • 2Comparing one year versus two years of the targeted medication olaparib.
  • 3Looking at the effects of adding the drug bevacizumab to the treatment plan.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Fallopian Tube Endometrioid AdenocarcinomaFallopian Tube High Grade Serous AdenocarcinomaFallopian Tube Malignant Mixed Mesodermal (Mullerian) TumorFIGO Stage III Ovarian Cancer 2014FIGO Stage IV Ovarian Cancer 2014Ovarian CarcinomaOvarian CarcinosarcomaOvarian High Grade Endometrioid AdenocarcinomaOvarian High Grade Serous AdenocarcinomaPrimary Peritoneal CarcinosarcomaPrimary Peritoneal Endometrioid AdenocarcinomaPrimary Peritoneal High Grade Serous Adenocarcinoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.